Lung cancer is the leading cause of cancer death in the U.S., with an estimated annual economic burden of $5 billion. Clinical trials offer innovative therapeutic options with potentially better outcomes, but their effects on health care costs are disputed.
Center for Cancer Economics, Technology Assessment, Innovation and Development (CETAID), Karmanos Cancer Institute, Detroit, Michigan 48201, USA. duw@karmanos.org